The Hb content, a sign of the risk of hemorrhagic transformation (HT) due to late IVT therapy, also remained unchanged between the groups with or without RIC therapy at 6 h post-stroke (p = 0.565; Figure 1F). This evidence concerns the gene GSTM1 and hematocrit.